Tevogen Bio Holdings (TVGN) Free Cash Flow (2022 - 2026)

Tevogen Bio Holdings has reported Free Cash Flow for 5 years, with the latest figure at -$2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow rose 17.36% year-over-year to -$2.7 million; the trailing twelve-month figure through Mar 2026 stood at -$11.8 million (up 10.57% YoY), and the FY2025 full-year result was -$12.4 million, down 3.29% from the prior year.
• Free Cash Flow for Q1 2026 stood at -$2.7 million, down from -$2.2 million in the prior quarter.
• The five-year high for Free Cash Flow was -$13861.0 in Q4 2022, with the low at -$3.8 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$2.1 million across 5 years, with a median of -$2.2 million in 2023.
• Annual changes were most pronounced in 2023 — Free Cash Flow plunged 14159.23% — and 2025, when it advanced 28.43%.
• Tevogen Bio Holdings' Free Cash Flow stood at -$13861.0 in 2022, then sank by 14159.23% to -$2.0 million in 2023, then plunged by 54.2% to -$3.0 million in 2024, then gained by 28.43% to -$2.2 million in 2025, then retreated by 25.33% to -$2.7 million in 2026.
• The last three Free Cash Flow figures came in at -$2.7 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.6 million (Q3 2025), per Business Quant data.